Innovative Cognitive Impairment Case Finding and Engagement for Diverse Participation in Alzheimer's Disease Care, Treatment, And Research

Launched by INDIANA UNIVERSITY · Jun 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new tool designed to help doctors identify patients who may have mild cognitive impairment (MCI) or Alzheimer's disease (AD) earlier and more accurately. Researchers at Indiana University have created a system called the Passive Digital Marker (PDM) that uses information from electronic health records to spot patients at risk of developing these conditions. The goal is to see if this tool can be successfully used in primary care settings to not only detect MCI and AD but also to encourage patients to participate in follow-up care and research.

To be part of this trial, participants need to be 65 years or older and already receiving care at one of the selected clinics at IU Health. They must also be identified as at high risk for MCI or AD through the PDM. Unfortunately, individuals younger than 65, new patients at IU Health, non-English or non-Spanish speakers, and those already diagnosed with MCI or AD cannot participate. If eligible, participants can expect to work with a specially trained nurse who will help assess their cognitive health and guide them through the next steps for care and evaluations if needed. This trial aims to improve how we detect and manage cognitive decline in older adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 65 years and older; established patients of 12 selected clinics at IU Health PC who are identified by the PDM as high risk for developing or having undetected MCI or ADRD.
• Exclusion Criteria:
• • Patients younger than 65 years; new patients to IUH (less than 12 months); individuals whose primary language is neither English nor Spanish; and current diagnosis of ADRD or MCI.